Ashina, Håkan
Iljazi, Afrim
Amin, Faisal M.
Ashina, Messoud
Lipton, Richard B.
Schytz, Henrik W.
Funding for this research was provided by:
Novartis Healthcare A/S
Article History
Received: 8 September 2020
Accepted: 10 November 2020
First Online: 19 November 2020
Ethics approval and consent to participate
: Informed written consent was obtained from each patient before conducting any study-related procedures. The study protocol was reviewed by the Regional Health Research Ethics Committee of the Capital Region of Denmark (identifier: H-18050498).
: Not applicable.
: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Dr. Faisal M. Amin has received personal fees from Eli Lilly, Novartis, and Teva. Dr. Faisal M. Amin is currently a principal investigator of clinical trials funded by Novartis and Teva. Dr. Faisal M. Amin is an associate editor of Headache Medicine. Dr. Messoud Ashina has received personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Eli Lilly, Novartis, and Teva. Dr. Messoud Ashina has been or is currently a principal investigator of clinical trials funded by Alder BioPharmaceuticals, Amgen, electroCore, Novartis, and Teva. Dr. Messoud Ashina is as an associate editor of Cephalalgia, Headache, and the Journal of Headache and Pain. Dr. Messoud Ashina reports research grants from the Lundbeck Foundation, Novo Nordisk Foundation, and Research Foundation of the Capital Region of Denmark. Dr. Richard B. Lipton is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the NIH: 2PO1 AG003949 (Multiple Principal Investigator), 5 U10 NS077308 (Principal Investigator), RO1 NS082432 (Investigator), 1RF1 AG057531 (Site Principal Investigator), RF1 AG054548 (Investigator), 1RO1 AG048642 (Investigator), R56 AG057548 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor), and 1K01AG054700 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology, senior advisor to Headache, and associate editor to Cephalalgia. He has reviewed for the NIA and NINDS; holds stock options in eNeura Therapeutics and Biohaven Holdings; and serves as consultant, advisory board member, or has received honoraria from the American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, electroCore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merc k, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. He receives royalties from Wolff’s Headache, 7th and 8th Edition, Oxford Press University, 2009, Wiley and Informa. Dr. Henrik W. Schytz has received speaking fees from Novartis, Eli Lilly, and Teva. Dr. Henrik W. Schytz has received a research grant from Novartis. The other authors declare no conflicts of interest.